1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor
  4. DP Isoform
  5. DP Agonist

DP Agonist

DP Agonists (7):

Cat. No. Product Name Effect Purity
  • HY-101987
    BW 245C
    Agonist 99.73%
    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
  • HY-111271
    L 888607
    Agonist 99.95%
    L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a Ki value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite.
  • HY-16504
    Treprostinil sodium
    Agonist 99.78%
    Treprostinil (UT-15) sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
  • HY-16751
    Agonist 99.79%
    Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
  • HY-113366
    Prostaglandin J2
    Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD).
  • HY-109163
    Treprostinil palmitil
    Agonist 99.56%
    Treprostinil palmitil (TP) is the proagent of DP1 and EP2 agonist, Treprostinil (UT-15), whose EC50 values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure proagent and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors.
  • HY-14898
    AGN 210676
    AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.